462 related articles for article (PubMed ID: 20159940)
21. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
Ratzon E; Najajreh Y; Salem R; Khamaisie H; Ruthardt M; Mahajna J
BMC Cancer; 2016 Feb; 16():140. PubMed ID: 26906901
[TBL] [Abstract][Full Text] [Related]
22. Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells.
Buß I; Hamacher A; Sarin N; Kassack MU; Kalayda GV
Metallomics; 2018 Mar; 10(3):414-425. PubMed ID: 29417972
[TBL] [Abstract][Full Text] [Related]
23. Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop.
Zhang W; Shi H; Chen C; Ren K; Xu Y; Liu X; He L
Phytomedicine; 2018 Sep; 48():51-61. PubMed ID: 30195880
[TBL] [Abstract][Full Text] [Related]
24. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.
Helleman J; Burger H; Hamelers IH; Boersma AW; de Kroon AI; Stoter G; Nooter K
Cancer Biol Ther; 2006 Aug; 5(8):943-9. PubMed ID: 16775422
[TBL] [Abstract][Full Text] [Related]
25. Role of copper transporters in resistance to platinating agents.
Rabik CA; Maryon EB; Kasza K; Shafer JT; Bartnik CM; Dolan ME
Cancer Chemother Pharmacol; 2009 Jun; 64(1):133-42. PubMed ID: 18998134
[TBL] [Abstract][Full Text] [Related]
26. Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Jaehde U
J Inorg Biochem; 2012 Nov; 116():1-10. PubMed ID: 23010323
[TBL] [Abstract][Full Text] [Related]
27. Mammalian copper homeostasis requires retromer-dependent recycling of the high-affinity copper transporter 1.
Curnock R; Cullen PJ
J Cell Sci; 2020 Aug; 133(16):. PubMed ID: 32843536
[TBL] [Abstract][Full Text] [Related]
28. Transporter-Mediated Interaction Between Platinum Drugs and Sorafenib at the Cellular Level.
Schneider V; Chaib S; Spanier C; Knapp M; Moscvin V; Scordovillo L; Ewertz A; Jaehde U; Kalayda GV
AAPS J; 2017 Nov; 20(1):9. PubMed ID: 29192345
[TBL] [Abstract][Full Text] [Related]
29. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
Shang X; Lin X; Manorek G; Howell SB
Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
[TBL] [Abstract][Full Text] [Related]
30. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells.
Beretta GL; Gatti L; Tinelli S; Corna E; Colangelo D; Zunino F; Perego P
Biochem Pharmacol; 2004 Jul; 68(2):283-91. PubMed ID: 15194000
[TBL] [Abstract][Full Text] [Related]
31. Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis.
Lai YH; Kuo C; Kuo MT; Chen HHW
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772714
[TBL] [Abstract][Full Text] [Related]
32. Role of copper transporters in the uptake and efflux of platinum containing drugs.
Safaei R
Cancer Lett; 2006 Mar; 234(1):34-9. PubMed ID: 16297532
[TBL] [Abstract][Full Text] [Related]
33. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.
Holzer AK; Samimi G; Katano K; Naerdemann W; Lin X; Safaei R; Howell SB
Mol Pharmacol; 2004 Oct; 66(4):817-23. PubMed ID: 15229296
[TBL] [Abstract][Full Text] [Related]
34. Distinct mechanisms for Ctr1-mediated copper and cisplatin transport.
Sinani D; Adle DJ; Kim H; Lee J
J Biol Chem; 2007 Sep; 282(37):26775-26785. PubMed ID: 17627943
[TBL] [Abstract][Full Text] [Related]
35. Interactions of cisplatin and the copper transporter CTR1 in human colon cancer cells.
Akerfeldt MC; Tran CM; Shen C; Hambley TW; New EJ
J Biol Inorg Chem; 2017 Jul; 22(5):765-774. PubMed ID: 28516214
[TBL] [Abstract][Full Text] [Related]
36. The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy.
Öhrvik H; Thiele DJ
J Trace Elem Med Biol; 2015; 31():178-82. PubMed ID: 24703712
[TBL] [Abstract][Full Text] [Related]
37. Expression profile of copper transporters in sensitive and cisplatin/oxaliplatin-resistant tumor cell lines.
Kassack MU; Stratenschulte C
Int J Clin Pharmacol Ther; 2005 Dec; 43(12):597-8. PubMed ID: 16372532
[No Abstract] [Full Text] [Related]
38. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
Rixe O; Ortuzar W; Alvarez M; Parker R; Reed E; Paull K; Fojo T
Biochem Pharmacol; 1996 Dec; 52(12):1855-65. PubMed ID: 8951344
[TBL] [Abstract][Full Text] [Related]
39. Uptake of compounds that selectively kill multidrug-resistant cells: the copper transporter SLC31A1 (CTR1) increases cellular accumulation of the thiosemicarbazone NSC73306.
Fung KL; Tepede AK; Pluchino KM; Pouliot LM; Pixley JN; Hall MD; Gottesman MM
Mol Pharm; 2014 Aug; 11(8):2692-702. PubMed ID: 24800945
[TBL] [Abstract][Full Text] [Related]
40. A role for the copper transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatment.
Landon CD; Benjamin SE; Ashcraft KA; Dewhirst MW
Int J Hyperthermia; 2013 Sep; 29(6):528-38. PubMed ID: 23879689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
